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Introduction: Targeted therapies for aggressive breast cancers like triple negative breast cancer (TNBC) are needed.
The use of small interfering RNAs (siRNAs) to disable expression of survival genes provides a tool for killing these
cancer cells. Cyclin dependent kinase 11 (CDK11) is a survival protein kinase that regulates RNA transcription,
splicing and mitosis. Casein kinase 2 (CK2) is a survival protein kinase that suppresses cancer cell death. Eliminating
the expression of these genes has potential therapeutic utility for breast cancer.
Methods: Expression levels of CDK11 and CK2 mRNAs and associated proteins were examined in breast cancer cell
lines and tissue arrays. RNA expression levels of CDC2L1, CDC2L2, CCNL1, CCNL2, CSNK2A1, CSNK2A2, and CSNK2B
genes in breast cancer subtypes were analyzed. Effects following transfection of siRNAs against CDK11 and CK2 in
cultured cells were examined by viability and clonal survival assays and by RNA and protein measures. Uptake of
tenfibgen (TBG) nanocapsules by TNBC cells was analyzed by fluorescence-activated cell sorting. TBG nanocapsules
delivered siRNAs targeting CDK11 or CK2 in mice carrying TNBC xenograft tumors. Transcript cleavage and response
parameters were evaluated.
Results: We found strong CDK11 and CK2 mRNA and protein expression in most human breast cancer cells.
Immunohistochemical analysis of TNBC patient tissues showed 100% of tumors stained positive for CDK11 with
high nuclear intensity compared to normal tissue. The Cancer Genome Atlas analysis comparing basal to other
breast cancer subtypes and to normal breast revealed statistically significant differences. Down-regulation of CDK11
and/or CK2 in breast cancer cells caused significant loss of cell viability and clonal survival, reduced relevant mRNA
and protein expression, and induced cell death changes. TBG nanocapsules were taken up by TNBC cells both in
culture and in xenograft tumors. Treatment with TBG- siRNA to CDK11 or TBG- siRNA to CK2αα’ nanocapsules
induced appropriate cleavage of CDK11 and CK2α transcripts in TNBC tumors, and caused MDA-MB-231 tumor
reduction, loss of proliferation, and decreased expression of targeted genes.
Conclusions: CDK11 and CK2 expression are individually essential for breast cancer cell survival, including TNBC.
These genes serve as promising new targets for therapeutic development in breast cancer.* Correspondence: trem0005@umn.edu
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Targeted therapies for hormone receptor expression
positive and for human epidermal growth factor recep-
tor 2 (HER2, also known as ERBB2 or EGFR2) overex-
pression-positive disease have improved breast cancer
mortality; however, breast cancer lacking these recep-
tors, termed triple negative breast cancer (TNBC), pre-
sents particular challenges because of its highly
aggressive nature. Given the need for new approaches
to treat TNBC, we investigated the effectiveness of
downregulation of the essential protein kinases cyclin-
dependent kinase (CDK) 11 and casein kinase 2 (CK2)
using RNA interference (RNAi) for killing this aggres-
sive form of breast cancer. When targeting a survival
gene, an RNAi or small interfering RNA (siRNA) ap-
proach to downregulate or eliminate the survival pro-
tein expression, and thus its function, has advantages of
great flexibility and specificity in choosing the target.
The difficulty in such an approach when moving to sys-
temic organismal use comes with delivery of the nu-
cleic acids in a protected and tumor-directed manner.
We have developed tenfibgen (TBG) nanoencapsulation
technology that allows for delivery of nucleic acids into
malignant cells in vivo while avoiding accumulation in
normal cells [1-3].
The first CDK family members characterized were the
catalytic subunits that formed heterodimers with regula-
tory partner proteins, called cyclins. The prototypical
CDKs (such as CDK1 and CDK2) displayed cell cycle
phase-specific activity; however, there are now members
of the CDK family that play more varied roles in cellular
regulation [4,5]. CDK11 (formerly named PITSLRE) is a
somewhat atypical CDK that is essential for cell survival
[6,7]. CDK11 is evolutionarily well conserved with two
almost identical CDK11 genes in humans (CDC2L1 and
CDC2L2) and one CDK11 gene in other organisms, in-
cluding mice [8]. Cyclin L1 (CCNL1) and cyclin L2
(CCNL2) are confirmed regulatory partner proteins for
CDK11 [9-14]. Expression of both CDK11 and cyclin L1
is increased in various cancers, with amplification of
CCNL1 associated with poor prognosis [15-20]. Tran-
scription and alternative splicing generate more than 20
distinct CDK11 mRNA and protein isoforms in human
cells, and the alternative splicing involves exons encod-
ing the N-terminal domain, but not exons in the C-
terminal kinase catalytic domain [8]. Gene mutation
does not play a significant role in CDK11 function in
cancer, and the majority of mutations reported are mis-
sense, suggesting again the essential nature of CDK11
function (Sanger COSMIC database).
The predominant CDK11 protein isoforms during cell
proliferation are designated p110 and p58 for their re-
spective observed mass by polyacrylamide gel electro-
phoresis (CDK11p110, CDK11p58). The CDK11p110protein isoforms are ubiquitously expressed in mamma-
lian tissues and cell lines during proliferation and
throughout the cell cycle [21]; moreover, CDK11p110
continues to be detected by immunoblot in quiescent
mouse liver [9]. The p110 isoforms associate with
multiple transcription and splicing related proteins via
the N-terminal (nonkinase) domain and have been
shown to influence transcription and splicing activities
[9,22-28]. The CDK11p58 isoforms are translated at the
G2/M cell cycle transition from an internal ribosomal
entry site on the same mRNA transcripts that produce
the p110 isoforms [29]. CDK11p58 is only produced dur-
ing a very narrow window, and is therefore difficult to
detect in unsynchronized cells. CDK11p58 is necessary
for successful mitosis and is involved with centrosome
maturation, bipolar spindle formation, and centriole
duplication [6,30-35].
The CK2 (formerly casein kinase II) enzyme is a well-
established cancer target with a heterotetrameric com-
position of two catalytic α and/or α' subunits (42 and
38 kDa, respectively) joined together by two β subunits
(28 kDa). CK2 phosphorylates a vast number of sub-
strates, thereby influencing a multitude of cellular pro-
cesses [36]. CK2 does not require specific activation, and
thus generally exhibits constitutive activity in cells with
minor fluctuations in expression or activity from various
signaling inputs [37-40]. CK2 is ubiquitous, its steady-
state levels are distinct for various cell types, and its
expression in different tissues under normal conditions
remains constant. However, increased CK2 protein
expression and activity is observed in a broad range of
cancers including breast cancer, correlates with in-
creased nuclear localization, is not associated with any
mutational changes in CK2 genes, and serves as a prog-
nostic indicator [41-49]. Notably, expression of CK2α in
the mouse mammary gland under control of the mouse
mammary tumor virus long terminal repeat (MMTV-
LTR) gave rise to a transgenic mouse model of breast
cancer [50]. Finally, suppression of apoptosis by CK2
supports its role in cell survival, thus decisively connect-
ing CK2 upregulation and function to the cancer cell
phenotype [42,51].
Owing to the essential roles for CDK11 and CK2 in
both cycling and noncycling cells, tumor-targeted deliv-
ery of a therapeutic is important. To accomplish pro-
tected tumor cell-specific in vivo delivery of siRNAs, the
nucleic acid is condensed and coated with a TBG protein
shell that is recognized by tenascin-C receptors
[2,52,53]. Tenascin-C-rich stroma has been observed
consistently adjacent to the epithelial cell nests of breast
[54] and other cancers; further, tenascin-C appears to
play a role in initiating and sustaining lung colonization
of breast cancer cells [55]. TBG nanocapsule cellular up-
take utilizes a lipid raft-mediated caveolar pathway
Kren et al. Breast Cancer Research  (2015) 17:19 Page 3 of 21[1,56]. The TBG-based nanocapsules containing siRNA
average 10 to 30 nm in size, display a slight negative
charge, and exist as uniform nonaggregated particles in
solution. The TBG-siCK2 nanocapsule has been shown
to be specific for malignant and not normal prostate
cells in culture, and a similar TBG-RNAi-CK2 nanocap-
sule has been shown to be specific for malignant and
not normal tissues in mice [1-3].
Our data presented herein demonstrate that both
CDK11 and CK2 kinases are well expressed in breast
cancer cells and are essential for cell survival. TBG
nanocapsules enter human TNBC cells, both in cell
culture and when systemically administered to mice
carrying xenograft tumors. TBG-siCDK11-treated or
TBG-siCK2-treated MDA-MB-231 tumors showed
reduced target protein expression and response parame-
ters that included decreased proliferation, tumor mass,
and tumor volume relative to controls.
Materials and methods
Cell lines and culture
MCF-10A, MCF-12A, MDA-MB-468, and BT-474 cells
were obtained from ATCC (Manassas, VA, USA). MDA-
MB-231 and MCF-7 cells were a gift from Dr David
Potter (University of Minnesota, MN, Minneapolis,
USA). Tamoxifen-resistant MCF-7 L (MCF-7LTamR) cells
were a gift from Dr Douglas Yee (University of Minnesota).
SUM-149 and SUM-190 cells were a gift from Dr Sofia
Merajver (University of Michigan, MI, Ann Arbor, USA).
Growth conditions include: MDA-MB-231 in Dulbecco’s
modified Eagle’s medium (DMEM)/F12 (SH30023; HyClone
Logan, Utah, USA), 10% fetal bovine serum (FBS), 1% peni-
cillin–streptomycin; MCF-7 in phenol-free DMEM/F12
(SH30272; Hyclone), 10% charcoal-stripped FBS, 10 μg/ml
bovine insulin, 1% penicillin–streptomycin; MCF-10A in
DMEM/F12, 5% horse serum, 20 ng/ml human epidermal
growth factor, 100 ng/ml cholera toxin, 10 μg/ml bovine in-
sulin, 500 ng/ml hydrocortisone; MCF-12A in DMEM/F12,
5% horse serum, 20 ng/ml human epidermal growth factor,
100 ng/ml cholera toxin, 10 μg/ml bovine insulin, 500 ng/ml
hydrocortisone; MDA-MB-468 in DMEM (11995; Gibco
Carlsbad, CA, USA), 10% FBS, 1% penicillin–streptomycin;
MCF-7 L/TamR in phenol-free DMEM/F12, 5% charcoal-
stripped FBS, 5 μg/ml bovine insulin, 1% penicillin–strepto-
mycin; SUM-149 in Ham’s F12 (11765; Gibco), 5% FBS,
5 μg/ml bovine insulin, 1 μg/ml hydrocortisone, 0.5 μg/ml
amphotericin B, 5 μg/ml gentamycin; and SUM-190 in
Ham’s F12, 0.5 g/l bovine serum albumin, 5 mM ethanol-
amine, 10 mM HEPES, 5 μg/ml transferrin, 10 nM 3,3′,5-
triiodo-L-thyronine, 50 nM sodium selenite, 5 μg/ml bovine
insulin, 1 μg/ml hydrocortisone, 0.5 μg/ml amphotericin B,
5 μg/ml gentamycin. Cells were grown in an incubator at
37°C with 5% carbon dioxide, with the exception of the
SUM cell lines that were grown with 10% carbon dioxide.All cells had undetectable levels of mycoplasma when
thawed, and were maintained in culture for up to 3 months.
The MDA-MB-231, SUM-149, SUM-190, MCF-7, and
MCF-7LTamR cell lines were authenticated by STR profiling
(IDEXX BioResearch, Columbia, MO, USA).
Oligonucleotides
Standard chemistry siRNAs were obtained from Dharmacon
(Lafayette, CO, USA). The sense strand sequences
are: siCK2, 5′-auacaacccaaacuccacauuudTdT-3′ [2]; siCDK11,
5′-gagcgagcagcagcgugugdTdT-3′ [30]; and siCON1, 5′-
uagcgacuaaacacaucaauudTdT-3′ [57].
Immunofluorescence and immunohistochemical analyses
Ki-67 staining was performed by the Pathology and
Laboratory Medicine Service (Minneapolis VA Health
Care System, Minneapolis, MN, USA). Analysis of the
Ki-67 staining was performed using the ImmunoRatio
web application [58].
CDK11 staining was tested by immunofluorescence ana-
lysis in cultured cells and by immunohistochemical analysis
in xenograft tumor tissues using anti-CDK11 rabbit
polyclonal antibodies from Santa Cruz Biotechnology
(PITSLRE sc-928; Santa Cruz, CA, USA) and from
Bethyl Laboratories (A300-311A; Montgomery, TX,
USA). A negative control section (without primary anti-
body) was included in the testing to verify the specificity
of the signal. The Bethyl Laboratories antibody was chosen
for immunofluorescence work and the Santa Cruz anti-
body was chosen for immunohistochemical work.
For immunofluorescence analyses, breast cancer cells
were plated onto glass coverslips precoated with either
poly-D-lysine at 0.5 mg/ml (P6407; Sigma St. Louis,
MO, USA) or with Matrigel at 0.33 mg/ml (354234; BD
Biosciences San Jose, CA, USA). Next day, the cells were
fixed in 2% paraformaldehyde for 15 minutes at room
temperature, washed three times in phosphate-buffered
saline (PBS), incubated for 30 minutes in glycine
(100 mM, pH 7.4), and washed three times in PBS. The
fixed cells were permeabilized with 0.1% Triton X-100/
PBS for 3 minutes, and then washed three times in PBS.
Cells were incubated with Sea Block containing 6 mg/ml
normal donkey for 30 minutes at room temperature,
washed once in PBS, then incubated with CDK11 anti-
body (A300-311A, 2 μg/ml; Bethyl Laboratories) in a hu-
midified container at 37°C for 1 hour. Cells were washed
three times for 5 minutes in PBS containing 0.05% Ige-
pal CA-630 (Sigma) and incubated with secondary anti-
body (donkey anti-rabbit F(ab′)2 DyLight-488 711-486-
152, 0.75 mg/ml in 50% glycerol, 1:400; Jackson Immu-
noresearch, West Grove, PA, USA) in a humidified con-
tainer at 37°C for 1 hour. Cells were washed six times
for 5 minutes in PBS containing 0.05% Igepal CA-630
and counterstained using Slowfade Gold containing
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were captured using an Olympus BX60 (Shinjuku, Toyko,
Japan) fluorescent microscope at 40× objective with a
digital color Q Imaging Retiga 2000R Fast1394 camera
(Surrey, British Columbia, Canada).
CDK11 immunohistochemical staining was performed
on the following commercially purchased arrays (US
Biomax, Inc. Rockville, MD, USA): T085, T088a; BR243f,
BR487 (TNBC); and BR1503b. The following statement
was taken from the US Biomax website: ‘All tissue is col-
lected under the highest ethical standards with the
donor being informed completely and with their con-
sent. We make sure we follow standard medical care
and protect the donors’ privacy. All human tissues are
collected under HIPPA approved protocols’. This work
was performed under Minneapolis VA Health Care
System Subcommittee on Research Safety protocol num-
ber 130601. Slides were deparaffinized by three changes
of xylene (10 minutes each). The sections were then
rehydrated by passing through graded ethanol (100% ×
10 minutes, 100% × 5 minutes, 95% × 5 minutes, 80% ×
5 minutes). Heat-induced antigen retrieval was per-
formed with a citrate-based antigen retrieval solution,
pH 6.0 (Rodent Decloaker, Biocare Medical, CA,
Concord, USA) for 30 minutes. The endogenous tissue
peroxidase activity was quenched with a 3 to 5% hydro-
gen peroxide solution in PBS for 10 minutes. The tissue
slides were blocked with Background Sniper Reagent
(Biocare Medical) in 5% skim milk for 30 to 60 minutes.
The slides were incubated with primary CDK11 antibody
(1:50, sc-938; Santa Cruz, CA, USA) overnight at 4°C.
The antigen–antibody complex was detected using
Rabbit-on-Rodent-HRP-Polymer for 30 minutes and the
betazoid 3,3′-diaminobenzidine peroxidase chromo-
genic kit (Biocare Medical). Hematoxylin (Vector Lab
Burlingame, CA, USA) was used as nuclear counterstain
and washed in Clarifier 2 and Bluing reagent (Thermo
Scientific Waltham, MA, USA) to obtain better cyto-
plasm to nuclear contrast. The slides then underwent de-
hydration processing using graded ethanol, and were washed
with xylene before addition of a coverslip with nonaqueous
permanent mounting medium (Permount; Fisher Scientific
Waltham, MA, USA). Images were captured in bright field as
described above.
Scoring for CDK11-positive staining was performed
by two independent observers and for each tissue
represented the mean of the two observers’ scores.
CDK11 staining was given an intensity rating (0, no
stain; 1+, faint nuclear stain; 2+, moderate nuclear stain;
3+, strong nuclear stain) and a distribution rating repre-
senting the percentage of positive cells (0, no positives;
1, <10% positive; 2, 10 to 50% positive; 3, >50% positive).
The final score per tissue section was the product of the
intensity and distribution ratings.Cell viability assays
Transfection complexes were formed combining 30 nM
single siRNA or 15 nM each of combined siRNAs with
10 μl Dharmafect 1 or 2 and OPTI-MEM in a total vol-
ume of 400 μl. After a 20-minute incubation, 1.6 ml
antibiotic-free media containing 10% FBS was mixed
in and the total volume added to cells at 50% confluence
on 60 mm plates. After 5 hours of incubation at 37°C/
5% carbon dioxide, an additional 2 ml complete media
were added to each plate. Next day, the cells were trypsi-
nized and cells were plated (8,000 cells for MDA-MB-
231 and SUM-149; 10,000 cells for MCF-7LTamR) into
four wells per transfection condition in Primaria 96-well
plates coated with 0.33 mg/ml Matrigel (354234; BD
Biosciences), 0.2 μg/ml tenascin-C (CC065; Millipore
Billerica, MA, USA) and 0.1 μg/ml fibronectin (F-0895;
Sigma). Ninety-six hours following transfection initi-
ation, CellTiter 96® Aqueous One Assays were per-
formed according to the manufacturer’s instructions
(Madison, WI, USA). Absorbance values for media alone
were subtracted from the experimental values. The data
shown represent the results of five experiments for
MDA-MB-231, of four experiments for SUM-149, and
of two experiments for MCF-7TamR.
Clonal survival assays
Cells were transfected as described above, and 48 hours
after the first transfection the cells were replated for 50
to 60% confluence the next day and transfected a second
time. Twenty-four hours after the second transfection,
the cells were collect using trypsin and plated in tripli-
cate at a concentration of 2,000 cells per 35 mm plate in
standard media. The media were replaced after 4 days,
and 7 days after plating the cells were stained with crys-
tal violet for 20 minutes (1× PBS containing 1% (v/v)
methanol, 1% (v/v) formaldehyde and 0.05% (w/v) crystal
violet), the stain removed, and plates washed by
immersion in water with continuous water flow. Plates
were air-dried, colonies containing at least 50 cells were
counted, and plates were scanned. The data shown rep-
resent the results of three replicates per experiment with
three experiments performed per cell line.
Immunoblot analysis
Cell pellets from cultured cells were processed in radio-
immunoprecipitation assay buffer and 20 μg subjected
to 8%, 10% or 12% Tris–glycine SDS-PAGE as described
previously [59]. For lysates from tumors, approximately
0.1 g frozen tumor tissue was minced and homogenized
on ice in 1 ml CSK buffer (10 mM PIPES pH 6.8,
300 mM sucrose, 3 mM MgCl2, 1 mM ethylenediamine
tetraacetic acid (EDTA), 0.5% Triton X-100) and centri-
fuged for 15 minutes at 600 × g at 4°C. This processing
resulted in extraction of the nuclear proteins into the
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ing supernatant was quantitated using the Bradford
assay (23238; Thermo Scientific), and 30 μg each lysate
were separated using the NuPAGE 4 to 12% Bis–Tris
and Novex 4 to 12% Tris–Glycine Midi gel systems (Life
Technologies Waltham, MA, USA). The membranes
were blocked for 30 minutes with 5% nonfat milk (170–
6404; Bio-Rad Hercules, CA, USA) or 5% bovine serum
albumin (A-9647; Sigma) in Tris-buffered saline (pH 7.4)
with 0.1% Tween 20 at room temperature. Antibodies
were diluted into fresh blocking buffer according to the
manufacturer’s recommendations, and the membranes
processed as described [59]. Antibodies used were: CDK11
(A300-311A), cyclin L1 (A302-058A), CK2α (A300-197A)
and CK2α′ (A300-199A) from Bethyl Laboratories; cyclin
L2 (600-401-878) from Rockland Immunochemicals
(Limerick, PA, USA); CK2β (sc-12739 and sc-46666) and
actin (sc-1616) from Santa Cruz Biotechnology; CDK11
(5524), caspase 3 (9661, 9662), lamin A/C (2032), and Bcl-
xL (2762) from Cell Signaling (Beverly, MA, USA); and sur-
vivin (AF886) from R&D Systems (Minneapolis, MN, USA).
Quantitative real-time RT-PCR analysis
Total RNA was isolated from frozen cell pellets using the
RNeasy mini kit (Qiagen Valencia, CA, USA), including the
on-column DNase digestion according to the manufacturer’s
protocol, and quantitated using a NanoDrop spectropho-
tometer. The Superscript III kit (Invitrogen) was used to
synthesize cDNA from total RNA (0.25 μg) using oligo-dT
primers according to the manufacturer’s protocol. FAM Taq-
Man gene expression probes hs00751002_s1 (CK2α),
hs00176505_m1 (CK2α′), hs00414449_m1 (CDK11), and
hs01003267_m1 (HPRT-1), TaqMan Fast 2X Mastermix and
UNG amperase were from Applied Biosystems, Inc. (Foster
City, CA, USA). Reactions were run according to manufac-
turer’s specification using 96-well FAST plates on an ABI
7900HT machine (Applied Biosystems, Inc.). Analyses were
performed using the SDS 2.3 ABI software (Applied Biosys-
tems, Inc.) and changes calculated according to the 2(−ΔΔCt)
method. HPRT-1 was used as the reference gene for
normalization. All results are reported as the average of reac-
tions run in duplicate.
Nanocapsule preparation
For TBG nanocapsules, a dispersion atomization method
was used to package siRNA oligonucleotides into nano-
capsules composed of TBG. The modified method of
Aukhil and colleagues was used to prepare TBG [60]. All
other reagents used were of the highest purity available.
Briefly, 250 μg siRNA was complexed with 37.5 μg
spermine (0.5 μg/μl; Sigma-Aldrich St. Louis, MO, USA)
and dispersed using a water-insoluble surfactant system
consisting of 10 μg 2,4,7,9-tetramethyl-5-decyn-4,7-diol
(50% v/v) in dimethylsulfoxide (Air Products andChemicals, Inc. Allentown, PA, USA). Following emulsi-
fication into a water-insoluble surfactant dispersed into
a water-miscible solvent (dimethylsulfoxide), the siRNA
was then inverted by dilution into suspension with
addition of 750 μl sterile PBS, pH 7.2. The resultant
hydrophobic micelles were coated by adsorption to
12.5 μg TBG (1 μg/μl) dispersed into the solution prior
to spray dispersion atomization into a 25 ml LiCl salt so-
lution (135 mM Li+, 9 mM Ca2+, 37.5 nM Sr2+, 12.5 nM
Mg2+). Following incubation at 4 to 6°C with rotation in
the salt solution for more than 14 hours, the nanocap-
sules were recovered by centrifugation at 20,000 x g for
2 hours, and resuspended in PBS containing 10% lactitol
(w/v) at a theoretical concentration of 1 μg/μl for
0.2 μm filter sterilization prior to characterization. Aver-
age particle diameters were measured from transmission
electron microscopy images. Surface charge determina-
tions were confirmed by published methods [61].
Fluorescence-activated cell sorting analysis of cultured
cells and xenograft tumors
MDA-MB-231 (4 × 105) cells and SUM-149 (8 × 105)
cells were plated onto 60 mm plates precoated overnight
with 0.25 μg/ml of 3:1 tenascin-C (CC065; Millipore)/
fibronectin-1 (F089; Sigma). The media for MDA-MB-231
cells included 12 μl/ml human low-density lipoprotein to
improve nanocapsule uptake. The next morning, media
were replaced with 2 ml media containing 125 ng/ml
TBG-dysprosium (Dy). For MDA-MB-231 cells that were
treated twice with TBG-Dy, the media were again replaced
with 2 ml media containing 125 ng/ml TBG-Dy 12 hours
after the first treatment. The following morning, all cells
were 70 to 90% confluent and were collected and sub-
jected to fluorescence-activated cell sorting (FACS) ana-
lysis. A minimum of 10,000 events from each cell
transfection or untreated cells were collected. TBG-Dy up-
take by cells was determined by gating for Dy fluorescent
signal (em 625, Per-CP/Cy5.5 filter). Data were collected
and analyzed using a FACS ARIA III (Becton Dickinson
San Jose, CA, USA) and FACS DIVA software version 6.0
(BD Biosciences San Jose, CA, USA).
Mice carrying MDA-MB-231 or SUM-149 xenograft
tumors initiated in the mammary pad (~300 mm3) were
injected with 200 nmol/kg TBG-Dy by tail vein. Next
day, the tumors were collected on ice, finely minced,
and incubated at 37°C in 1× collagenase/hyaluronidase
(36254; StemCell Tech Vancouver, British Columbia,
Canada) in DMEM/F12 with 5% FBS at a ratio of 10 ml
solution per 1 g tumor. Digestion mixtures were mixed
using a transfer pipette every 15 minutes. After 60 mi-
nutes, an equal volume of Hank’s balanced salt solution
(SH30031.02; HyClone) with 2% FBS was added and the
cells centrifuged 350 × g for 5 minutes. Cells were resus-
pended in 2 ml of 0.05% trypsin/0.025 mM EDTA and
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was stopped by addition of 3 ml DMEM/F12 with 5% FBS
and centrifugation at 350 × g for 5 minutes. The cells were
resuspended and continuously pipetted for 1 minute in 2 ml
dispase (07913; StemCell Tech) prewarmed to 37°C contain-
ing 0.1 ml of 1 mg/ml DNase I (07900; StemCell Tech). Ten
milliliters of ice-cold Hank’s balanced salt solution with 2%
FBS were added to the digest, and the cells centrifuged at
350 × g for 5 minutes. Cells were resuspended in 5 ml red
blood cell lysis buffer (150 mM ammonium chloride,
10 mM potassium bicarbonate, 0.1 mM EDTA), followed by
20 ml ice-cold PBS, and centrifuged at 350 × g for 5 minutes.
Cells were resuspended in 5 ml ice-cold Hank’s balanced salt
solution with 2% FBS, passed sequentially through 100 μm
and 40 μm cell strainers and centrifuged at 350 × g for 5 mi-
nutes. The final cell pellet was resuspended in 2 ml DMEM.
FACS analysis was performed as above on the tumor cell
suspensions collecting 100,000 events.
5′ RNA ligase-mediated RACE
MDA-MB-231 xenograft and SUM-149 mammary pad
tumors from different acute dosing experiments were
used for total RNA isolation using TRIzol (Life Tech-
nologies), and the quality of RNA was verified by gel
electrophoresis. Total RNA (10 μg) from the tumors was
ligated with 0.5 μg RNA adaptor oligomer (5′-cgacug-
gagcacgaggacacugacauggacugaaggaguagaaa-3′) that con-
tains the forward 5′ adaptor primer binding site in a
20 μl reaction using 20 U RNA ligase (New England
Biolabs Ipswich, MA, USA) and 40 U RNaseOUT™ (Life
Technologies) according to the manufacturer’s recom-
mended conditions. The ligated RNA was purified by dia-
filtration (Ultracel-30 K; Millipore) using conditions for
nucleic acids outlined by the manufacturer, and the quality
of the ligated RNA product was verified by gel electrophor-
esis. Eight microliters of the ligated RNA product were re-
verse transcribed using Superscript III (Life Technologies)
and a CDK11 gene-specific primer (5′-ACAAAGTAA-
GACGAGGAGTTCCGAG-3′), a CK2α gene-specific pri-
mer (5′-CGCTTTCGAGAGTGTCTGCCCAAGA-3′), or
a CK2α′ gene-specific primer (5′-GGTGTCTGTTCTCA
CTATGG-3′) designed to hybridize 3′ to the predicted
RNAi-mediated cleavage sites in the respective transcripts.
The resulting cDNAs (2 μl) were used for PCR using the
forward RNA adaptor primer (5′-GGACACTGACATGG
ACTGAAGGAGTA-3′) and the reverse CDK11 (5′-TGGT
GGTAAGGTGGAAGCCCGTCTC-3′), CK2α (5′-TCACT
GTGGACAAAGCGTTCCCATC-3′), or CK2α′ (5′-TGGA
TAAAGTTTTCCCAGCG-3′) gene-specific primer. PCR
was performed using the Expand High Fidelity system
(Roche Applied Science Indianapolis, IN, USA) using
dNTP, buffer and enzyme concentrations recommended by
the manufacturer. PCR for CK2αα′ RACE products was per-
formed using 95°C for 3 minutes, 40 cycles of amplification(94°C for 45 seconds, 57°C for 30 seconds, 72°C for 45 sec-
onds), and 72°C for 10minutes. CDK11 RACE products were
amplified using 94°C for 2 minutes; five cycles of 94°C for
30 seconds and 72°C for 1minute; 34 cycles of 94°C for 45 sec-
onds, 65°C for 30 seconds, 72°C for 45 seconds; and 72°C for
10minutes. PCR products were analyzed by 2% agaroseTris–
borate–EDTA gel electrophoresis stained with ethidium
bromide and visualized by UV light. Oligomers were obtained
from IntegratedDNATechnologies (Coralville, IA, USA).Mouse xenograft therapeutic acute effect studies
Female athymic NCr nude (Nu/Nu) mice (01B74; National
Cancer Institute Frederick,MD,USA)weremaintained under
pathogen-free conditions. MDA-MB-231 tumors were initi-
ated by subcutaneous injection of 2 × 106 cells in 50%Matrigel
(354234; BD Biosciences) in the mouse flank when mice were
7 to 8 weeks old. Therapy was initiated when tumors reached
an average size of 150mm3, calculated using the formula:
Volume ¼ length  width  widthð Þ = 2
Groups of mice (six to seven mice per group) were
subjected to intravenous injection on days 1, 4 and 7
with 0.01 mg/kg TBG-siCDK11, TBG-siCK2, or TBG-
siCON1 in Plasma-Lyte-A (Baxter Deerfield, IL, USA).
Mice were sacrificed on day 10, and the tumor, liver, spleen,
kidney, ovary, and normal mammary pad were excised,
weighed, and snap frozen in liquid nitrogen for protein analysis
orwere placed in formalin. The animal facilitieswere approved
by the Association for the Assessment and Accreditation of
Laboratory Animal Care International and all animal research
was performed in strict accordance with the recommenda-
tions in theGuide for the Care andUse of Laboratory Animals
and with the current regulations and standards of the USDA,
the US Department of Health and Human Services, and the
National Institutes of Health. Animal experiments were con-
ducted in the Minneapolis VA Health Care System animal fa-
cility in accordance with a protocol approved by the
Minneapolis VA Health Care System Institutional Animal
Care andUseCommittee (protocol number 130601).Image processing
Immunoblot images from the siRNA-transfectedcultured
cells were adjusted in size to align lanes from different
comb sizes. Black lines on immunoblots and white lines
on agarose gels indicate removal of intervening lanes.
Adobe Photoshop adjustments were made. No gamma
changes were made to any image. For immunofluores-
cence and transmission electron microscopy images,
contrast was adjusted to +100. For immunohistochemistry
(IHC) images, brightness was adjusted to +100 and con-
trast to +50.
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IHC scores for the CDK11 signal on human breast cancer
arrays were determined by two independent observers. The
average value was taken for each sample. The comparison
between normal tissue and TNBC was conducted using a
Wilcoxon rank-sum test and the median and range for each
are reported. Mean immunoblot protein levels, cell viability
values, and the number of clonal survival colonies were
summarized and compared by treatment group using ana-
lysis of variance (ANOVA). The mean ± standard deviation
is presented unless otherwise indicated. Mouse tumor vol-
umes on days 7, 9 and 10 (relative to day 1) and primary
tumor weights were summarized and compared by treat-
ment group using ANOVA. P values for pairwise compari-
sons for the above analyses were conservatively adjusted for
multiple comparisons using a Bonferroni correction. Differ-
ences between mouse weights on day 10 were compared by
treatment group using paired t tests. The percentage of
Ki67-positive cells was compared by treatment using
ANOVA, adjusting for repeated measures within mice.
Least-squares means ± standard errors are presented. P
values for these comparisons with the control group were
adjusted for multiple comparisons using Dunnett’s method.
TCGA breast cancer RSEM-normalized read count
RNASeq (v.2, level 3) data were downloaded from The
Cancer Genome Atlas data portal (November 2014) and as-
sociated metadata (PAM50 RNAseq calls, sample type data)
were downloaded from the UCSC Cancer Genome Browser
(November 2014). Log2-transformed RSEM normalized
read counts were used as the final gene expression meas-
urement. ANOVA and Student t tests were used to test for
differences in expression for seven genes between basal
breast cancer subtype and normal or other subtype primary
tumors. P values for pairwise comparisons were conserva-
tively adjusted for multiple comparisons using a Bonferroni
correction. P <0.05 values are reported and considered sta-
tistically significant for all analyses.Table 1 Characteristics of breast cancer cell lines
Cell linea Transformed Molecular subtype Histological
MCF-10A No Basal Fibrocystic
MCF-12A No Basal Fibrocystic
BT-474 Yes Luminal B DC
MCF-7 Yes Luminal A AC
MCF-7LTamR Yes Luminal A AC
MDA-MB-231 Yes Basal AC
MDA-MB-468 Yes Basal AC
SUM-149 Yes Basal IBC
SUM-190 Yes Basal IBC
AC, adenocarcinoma; DC, ductal carcinoma; ER, estrogen receptor; IBC, inflammator
factor receptor 2. aMCF-10A and MCF-12A are spontaneously immortalized cells. bOResults
Expression of CDK11 and CK2 protein complex
constituents in breast cancer cells
We examined the steady-state protein expression levels
for CDK11 and CK2 protein complex members in breast
cancer cell lines representing a range of subtypes. We also
included nontransformed, immortalized cell lines (see
Table 1). CDK11p110 and partner cyclins L1α and L2α
were well expressed in these cell lines, with the exception
of SUM-190 (Figure 1A). CDK11p110 was detected in
SUM-190 cells upon longer exposure. In these breast
cancer cell lines, detection of CDK11 displayed the
prominent CDK11p110 isoform along with lesser expres-
sion of slightly smaller alternatively spliced isoforms, as
has been observed previously [8,9]. Cyclin L1α is de-
tected as a doublet or triplet when using radioimmuno-
precipitation assay buffer, which can be observed in
SUM-190 lysate due to the lower expression level. Cyc-
lin L2α was detected as a single band. CK2α and CK2α′
proteins were simultaneously detected and demon-
strated strong expression levels. The expression level of
CK2α′ relative to CK2α was unusually high in the in-
flammatory breast cancer cells, suggesting a possible
role for CK2α′ in inflammatory breast cancer. CK2β
was moderately expressed in all cell lines.
Intracellular protein expression patterns for CDK11 and
CK2αα′ in nontransformed MCF-10A cells were examined
by indirect immunofluorescence (Figure 1B). CDK11 pro-
teins were detected mainly in the nuclei with prominent
transcription and pre-mRNA splicing speckle distribution
and more diffuse nucleoplasmic localization, as has been
seen in nonbreast cell lines [9]. CK2α and CK2α′ proteins
were localized in both nuclei and cytoplasm with a much
stronger, finely speckled nuclear signal than cytoplasmic
signal. CDK11 protein localization in TNBC cells was also
evaluated and found to mirror that observed in the non-
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Figure 1 Expression of CDK11 and CK2 protein complex members in untransformed and malignant breast cells. (A) Immunoblot analysis
of cultured breast cell lines, as indicated above the blots. Proteins detected are indicated on the right side of the blots. Actin signal was used as
the loading control. (B) Indirect immunofluorescent detection of CDK11, CK2α, and CK2α′ (red color) in breast cell lines. Cell lines are indicated
above each set of images and proteins detected are indicated on the left side of the images. Blue, 4′,6-diamidino-2-phenylindole-stained nuclei.
Scale bar: 100 μm. (C) Immunohistochemical detection of CDK11 proteins in human normal and malignant breast tissue. Type of breast tissue
indicated on the left side of the images. Magnification indicated above the images; dotted ellipse, portion of the 100× image that is shown at
400×. Scale bars: 400 μm for 100× and 100 μm for 400× images. (D) Human microarray tissues stained for CDK11 were scored by two
independent observers. The average value was taken and the results plotted for normal (n = 16) versus triple-negative breast cancer (TNBC;
n = 44) tissues. Box, first to third (Q1 to Q3) quartiles; diamond, mean; line inside box, median; whiskers, minimum and maximums of data range.
CDK, cyclin-dependent kinase; CK2, casein kinase 2.
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breast cancer cells
We investigated how transcript expression related to
protein expression in the nontransformed and TNBC
cells for CDK11, CK2α and CK2α′. Data fromquantitative real-time RT-PCR are summarized in
Table 2. In general, protein expression and mRNA ex-
pression levels were similarly related for the TNBC cells.
For example, in MDA-MB-468 cells roughly equal
amounts of CK2α and CK2α′ protein levels are detected
Table 2 mRNA expression levels in nontransformed and
malignant breast cellsa
Cell line CDK11b CK2α CK2α′
MCF-10A 1.53 ± 0.04 2.90 ± 0.35 5.19 ± 0.36
MCF-12A 1.38 ± 0.07 1.91 ± 0.17 1.05 ± 0.03
MDA-MB-231 0.96 ± 0.10 2.91 ± 0.48 0.40 ± 0.004
MDA-MB-468 0.87 ± 0.11 3.18 ± 0.06 2.91 ± 0.39
SUM-149 0.31 ± 0.001 0.66 ± 0.08 1.84 ± 0.01
Data presented as mean ± standard error. amRNA expression normalized to
HPRT-1. bBoth human genes (CDC2L1 and CDC2L2) recognized by PCR probes.
Kren et al. Breast Cancer Research  (2015) 17:19 Page 9 of 21(Figure 1A), and likewise roughly equal amounts of the
corresponding mRNA transcripts are expressed. In the
nontransformed MCF-10A and MCF-12A cells, equal
amounts of CK2α and CK2α′ proteins are expressed but
the relative amounts of their corresponding mRNAs
differ. For CDK11, more mRNA is expressed in MDA-
MB-231 and MDA-MB-468 cells than in SUM-149 cells,
which matches the relative amounts of CDK11p110
protein detected. In contrast, the nontransformed MCF-
10A and MCF-12A breast cells expressed roughly 1.6-
fold greater CDK11 mRNA relative to MDA-MB-231
and MDA-MB-468, but expressed equal or lesser
amounts of protein.
CDK11 proteins are highly expressed in human triple-
negative breast cancer tissue
We also examined CDK11 protein expression in human
normal and malignant breast tissue using tissue microar-
rays. The antibody used for detection of CDK11 in the
tissues recognizes the carboxy terminus of both
CDK11p110 and CDK11p58 isoforms; however, because
CDK11p58 is typically only detected in cells transitioning
from G2 to mitosis cell cycle phases, the vast majority of
CDK11 detected in tissue array samples represents the
CDK11p110 isoforms. IHC CDK11 staining specificity
was verified by comparing results using two different
commercial antibodies on human xenograft tumor
tissues (data not shown). Upon staining of the tissue mi-
croarrays, CDK11 signal was observed in both malignant
and normal tissue (Figure 1C). Unlike cells proliferating
in culture, cells in normal breast tissue are less likely to
be actively proliferating; however, the CDK11p110 iso-
forms have function in nondividing cells as well as ac-
tively proliferating cells, and thus were detected in
normal breast epithelial cells as well as malignant cells.
CDK11 protein expression in the breast tissues, as mea-
sured by IHC, was evaluated; the median score in TNBC
was 7.5 (range 5.0 to 9.0) and was statistically signifi-
cantly greater than the score in normal breast tissue (3.5
(range 1.8 to 7.5)) (Figure 1D). Overall, CDK11 staining
was predominantly nuclear in both normal and TNBC
tissues, with higher intensity and higher percentage ofpositive cells in TNBC (P <0.0001). The higher level of
CDK11 protein signal in human TNBC observed here
compared with normal breast is in agreement with the
shift from moderate expression in breast glandular and
myoepithelial cells to moderate–strong expression in
breast cancer as documented on the Human Protein
Atlas website [62,63].
IHC results for increased CK2α protein expression, es-
pecially in the nucleus, and correlation with metastatic
risk in human breast cancer tissues have been published
previously [44,64], and specific staining for CK2αα′ in
human TNBC tissues was not performed here.
Expression of CDK11 and CK2 protein complex genes in
human breast cancer subtypes
Given the increased intensity of CDK11 protein signal in
the TNBC tissues, we examined the mRNA transcript
expression levels for CDK11 (CDC2L1, CDC2L2) using
The Cancer Genome Atlas RNAseq data. We performed
the same analysis for cyclin L1 (CNCL1), cyclin L2
(CNCL2), CK2α (CSNK2A1), CK2α′ (CSNK2A2), and
CK2β (CSNK2B). We used the PAM50 subtypes to com-
pare transcript expression in basal-subtype breast cancer
with normal breast tissue and with the other breast can-
cer subtypes. The data are summarized in Figure 2 and
Table 3. CDK11A showed no significant differences in
mRNA expression compared with normal breast and
with other breast cancer subtype tissues, and CDK11B
expression in the basal subtype demonstrated a signifi-
cant increase in mRNA expression relative to luminal B.
Cyclin L1 mRNA expression was significantly lower in
basal than normal tissue, but significantly higher than all
other breast cancer subtypes. Cyclin L2 transcript ex-
pression was also significantly lower in basal breast can-
cer than in normal breast. CK2α mRNA expression was
significantly higher in the basal subtype than in normal
tissue and the luminal A subtype. CK2α′ transcript
levels were the same in the basal subtype as in normal
tissue and significantly higher in the basal subtype than
in HER2, luminal A, and luminal B cancers. Finally,
CK2β mRNA expression in basal breast cancer was sig-
nificantly higher than normal tissue and all other breast
cancer subtypes. In these RNAseq analyses, the basal
subtype was used as a surrogate for TNBC; additionally,
we found highly similar expression patterns when com-
paring TNBC with all other biomarker breast cancers
using microarray datasets found on Oncomine [65] (data
not shown).
siRNA-mediated downregulation of CDK11 and CK2 in
breast cancer cells induces death signaling, decreases cell
viability, and inhibits clonal survival
We used siRNA sequences previously validated for both
CDK11 gene transcripts, located 3′ to the CDK11p58
Figure 2 RNA expression levels in normal breast and breast cancer subtypes. Normalized RNAseq read count data for PAM50 breast cancer
subtypes and normal breast from The Cancer Genome Atlas were analyzed for CDK11 and CK2 protein complex genes as shown above each
plot. Box, first to third (Q1 to Q3) quartiles; line inside box, median; whiskers, 1.5 maximum interquartile range. Normal, n = 95; basal, n = 141;
Her2, n = 67; LumA, n = 421; LumB, n = 192. CDK, cyclin-dependent kinase; CK2, casein kinase 2; Her2, human epidermal growth factor receptor 2;
LumA, luminal A; LumB, luminal B.
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CK2α′ catalytic subunit gene transcripts to test the
effects of downregulation of CK2 alone, CDK11 alone,
or combined CK2 and CDK11 in breast cancer cells
[2,30]. Transfection of siCDK11 efficiently reduced
CDK11p110 protein expression in MDA-MB-231 and
SUM-149 cells by 72 hours post transfection (Figure 3).
CDK11p58 was not detectable in these asynchronously
growing cells. Loss of CDK11 expression did not have a
consistent effect on cyclin L1α or cyclin L2α expression
levels; however, downregulation of CDK11 resulted in
faster migration of the cyclin L2α protein. We also
observed that transfection of cultured cells frequently
caused increased detection of cyclin L1α protein. Trans-
fection of siCK2 significantly reduced expression of
CK2α and CK2α′ at 72 hours in MDA-MB-231 and
SUM-149 cells; concomitantly, CK2β expression levels
were also significantly reduced (Figure 3). Interestingly,
loss of CK2 also resulted in altered cyclin L2α migration.
Loss of CK2 and/or CDK11 expression resulted in
modulation of cell death associated gene expression at
96 hours post transfection. Reduced detection of full-
length caspase 3 protein was observed (Figure 3), and
activated caspase 3 cleavage products were also some-
times detected (data not shown). Decreased full-length
lamin A/C and appearance of cleaved lamin A/C prod-
ucts were also observed (data not shown). Loss of Bcl-xL
expression was more evident with knockdown of CDK11
than CK2 in both cell lines, whereas slight loss ofsurvivin expression was mainly seen following combined
kinase knockdown. Quantitative analysis of protein ex-
pression is summarized in Table 4.
The specificity of the CDK11 and CK2 siRNAs for tar-
geting the intended genes was examined by quantitative
real-time RT-PCR. MDA-MB-231 and SUM-149 cells
were transfected with 30 nM siRNAs (siCDK11, siCK2,
siControl), cells were collected at 24 hours post transfec-
tion, and quantitative real-time RT-PCR was performed.
CDK11 mRNA was decreased to 59% in both cell lines
by siCDK11 transfection (Table 5). Strong downregula-
tion of CK2α and CK2α′ mRNAs to less than 20% was
observed in both TNBC cell types. Neither siCK2 nor
siCDK11 transfections resulted in off-target decreased
expression of CDK11 or CK2αα′ mRNAs, respectively
(Table 5). Decreased protein expression for the targeted
mRNAs was observed at 48 hours (data not shown).
The viability of cells following a single transfection of
siCDK11, siCK2, or combined siCK2/siCDK11 was mea-
sured in MDA-MB-231, SUM-149, and MCF-7TamR cell
lines using the CellTiter 96® Aqueous One assay. Trans-
fected cells were plated into wells coated with Matrigel,
tenascin-C, and fibronectin to more closely mimic the
in vivo tumor cell environment. Significant reductions in
cell viability were observed for all three transfection
types for SUM-149 and MCF-7TamR cells; whereas sig-
nificant reductions in viability were observed in MDA-
MB-231 cells for siCDK11 and siCK2/siCDK11, but not
siCK2 alone (Figure 4A). Given that visual observation
Table 3 mRNA expression levels in normal and breast cancer subtypes
Gene Subtype or normala Log2(normalized counts)
b Comparison with basalc
CDC2L1 Normal 9.39 ± 0.38 0.90
Basal 9.51 ± 0.5 N/A
Her2 9.45 ± 0.61 1
Luminal A 9.46 ± 0.4 1
Luminal B 9.33 ± 0.57 0.049
CDC2L2 Normal 8.35 ± 0.76 −d
Basal 8.37 ± 0.79 N/A
Her2 8.49 ± 0.84 –
Luminal A 8.44 ± 0.69 –
Luminal B 8.24 ± 0.95 –
CCNL1 Normal 10.82 ± 0.58 1.37 × 10−14
Basal 10.15 ± 0.56 N/A
Her2 9.7 ± 0.49 9.68 × 10−7
Luminal A 9.87 ± 0.55 2.17 × 10−5
Luminal B 9.85 ± 0.49 2.10 × 10−5
CCNL2 Normal 10.79 ± 0.48 1.90 × 10−11
Basal 10.2 ± 0.71 N/A
Her2 10 ± 0.73 1
Luminal A 10.38 ± 0.7 0.21
Luminal B 10.28 ± 0.7 1
CSNK2A1 Normal 10.22 ± 0.2 5.50 × 10−15
Basal 10.74 ± 0.64 N/A
Her2 10.75 ± 0.51 1
Luminal A 10.53 ± 0.39 9.20 × 10−3
Luminal B 10.68 ± 0.61 1
CSNK2A2 Normal 9.36 ± 0.3 1
Basal 9.3 ± 0.39 N/A
Her2 8.92 ± 0.56 3.89 × 10−5
Luminal A 8.56 ± 0.45 2.06 × 10−49
Luminal B 8.64 ± 0.47 2.99 × 10−33
CSNK2B Normal 10.96 ± 0.28 3.03 × 10−38
Basal 11.78 ± 0.5 N/A
Her2 11.52 ± 0.39 1.91 × 10−3
Luminal A 11.25 ± 0.42 4.04 × 10−22
Luminal B 11.43 ± 0.54 8.24 × 10−8
Her2, human epidermal growth factor receptor 2; N/A, not applicable. aNormal, n = 95; basal, n = 141; Her2, n = 67; luminal A, n = 421; luminal B, n = 192. bRNAseq
data from The Cancer Genome Atlas expressed as mean ± standard deviation. cComparison with basal subtype, P value with Bonferroni correction; significant
P values in bold type. dAnalysis of variance comparing CDC2L2 expression across subtypes revealed no significant differences, so no pairwise t tests
were performed.
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231 cells were, in fact, dying due to siCK2 transfection,
we decided to use a different assay to evaluate cell sur-
vival following transfection of the different siRNAs. The
clonal survival assay was employed in which MDA-MB-
231 and SUM-149 cells were transfected twice with the
siRNA combinations – once on day 1 and once on day4. Twenty-four hours after the second transfection, the
cells were collected using trypsin and plated in triplicate
at 2,000 cells per 35 mm plate. After 7 days of incuba-
tion, the cell colonies were stained with crystal violet
and counted. Downregulation of CDK11, CK2, or com-
bined CDK11/CK2 protein expression resulted in highly
significant loss of cell survival in SUM-149 cells and
Figure 3 Immunoblot analyses following small interfering RNA-mediated downregulation of CDK11 and CK2 in breast cancer cells.
Immunoblot analysis of MDA-MB-231 and SUM-149 cell lysates following small interfering RNA (siRNA) transfection. Transfected siRNAs are
indicated above the blots, proteins detected are indicated on the right side of the blots. CDK11p110, cyclin L1α, cyclin L2α, and CK2αα′β lysates
are 72 hours post transfection; caspase 3, Bcl-xL, and survivin lysates are 96 hours post transfection. Actin signal was used as the loading control.
CDK, cyclin-dependent kinase; CK2, casein kinase 2.
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cells (Figure 4B). Representative crystal violet stained
colonies are shown in Figure 4C.
Tenfibgen nanocapsules enter cultured and xenograft
triple-negative breast cancer cells
To evaluate the in vivo effects on tumor growth of treat-
ment with siCDK11 or siCK2, we employed a unique
sub-50 nm size (that is, <50 nm) TBG-based nanocap-
sule that is capable of protected intracellular delivery of
siRNA cargos in a malignant cell-specific manner [1-3].
Figure 5A and Table 6 define the physical characteristics
of the TBG nanocapsules used in the therapeutic treat-
ment studies. For the purpose of quantifying nanocap-
sule uptake, we used TBG nanocapsules containing a
dysprosium dextran cargo. Dy is a fluorescent lanthanide
element. To establish the feasibility of FACS analysis for
Dy, MDA-MB-231 and SUM-149 cells were grown on
combined tenascin-C and fibronectin matrix, treated in
culture with TBG-Dy nanocapsules, and collected 1 day
later for FACS analysis of the Dy content. Untreated
cells were used to establish the analysis gate. Dy-positive
cells totaled 14.4% in the MDA-MB-231 cells (Figure 5B,
left panel and Table 7) and 13.1% in the SUM-149 cells
(Table 7). Additionally, MDA-MB-231 cells were treatedonce in the morning and again 12 hours later to evaluate
whether further uptake could be achieved. A 1.49-fold
increase in Dy-positive cells was achieved by a second
treatment (Figure 5B, right panel and Table 7).
Having established TBG-Dy FACS methodology, we
wished to quantitate the delivery of TBG nanocapsules
to tumor cells in vivo after one intravenous treatment.
Mice carrying MDA-MB-231 or SUM-149 mammary
pad xenograft tumors were injected via the tail vein with
TBG-Dy nanocapsule. After 24 hours, tumors were
collected from the TBG-Dy-injected mice as well as
non-injected control mice and subjected to dissociation.
FACS analysis for Dy signal was performed, using the
naive tumor cells to establish the gate (Figure 5C, left
panels). After just one injection, an average of 33.9 ± 4.7%
of the SUM-149 tumor cells was Dy-positive and 11.0% of
the MDA-MB-231 tumor cells were positive for Dy signal
(Figure 5C, right panels and Table 7).
Treatment with TBG-siCDK11 or TBG-siCK2 nanocapsules
causes MDA-MB-231 xenograft tumor shrinkage and loss
of proliferation
To demonstrate specific efficacy of CDK11 or CK2
targeting in vivo via TBG siRNA nanocapsules, we
performed an acute response study in which nude mice
Table 4 Protein expression levels following small interfering RNA transfection
siRNA CDK11 Cyclin L1α Cyclin L2α CK2α CK2α′ CK2β Caspase 3 – full
length
Bcl-xL Survivin
MDA-MB-231 siCDK11/CK2 0.09 ± 0.02 3.07 ± 1.56 0.73 ± 0.53 0.07 ± 0.08 0.05 ± 0.06 0.03 ± 0.03 0.45 ± 0.17 0.40 ± 0.38 0.73 ± 0.53
P <0.0001 P <0.0001 P = 0.001 P <0.0001
siCK2 0.98 ± 0.17 1.82 ± 0.67 0.78 ± 0.45 0.07 ± 0.07 0.05 ± 0.06 0.06 ± 0.04 0.85 ± 0.57 0.62 ± 0.10 0.85 ± 0.33
P <0.0001 P = 0.001 P <0.0001
siCDK11 0.04 ± 0.07 2.38 ± 0.18 0.91 ± 0.49 0.88 ± 0.17 1.13 ± 0.18 1.05 ± 0.15 0.57 ± 0.23 0.24 ± 0.05 0.79 ± 0.21
P <0.0001 P = 0.022
siControl 0.90 ± 0.04 1.77 ± 0.31 1.44 ± 0.62 1.09 ± 0.10 0.98 ± 0.26 1.14 ± 0.04 0.99 ± 0.07 0.93 ± 0.32 1.02 ± 0.20
SUM-149 siCDK11/CK2 0.44 ± 0.04 1.05 ± 0.12 1.30 ± 0.48 0.06 ± 0.05 0.27 ± 0.10 0.25 ± 0.14 0.45 ± 0.17 0.31 ± 0.21 0.77 ± 0.33
P <0.0001 P <0.0001 P = 0.0004 P = 0.001 P = 0.036 P = 0.034
siCK2 0.86 ± 0.13 0.93 ± 0.18 1.31 ± 0.52 0.08 ± 0.07 0.31 ± 0.23 0.14 ± 0.07 0.55 ± 0.34 0.73 ± 0.12 1.02 ± 0.10
P <0.0001 P = 0.0007 P = 0.0004
siCDK11 0.40 ± 0.16 1.04 ± 0.05 1.00 ± 0.19 1.19 ± 0.14 0.96 ± 0.12 0.77 ± 0.26 0.62 ± 0.23 0.54 ± 0.31 0.98 ± 0.18
P <0.0001
siControl 0.89 ± 0.12 0.89 ± 0.26 0.90 ± 0.87 1.36 ± 0.27 1.05 ± 0.29 0.88 ± 0.17 0.92 ± 0.24 1.08 ± 0.30 0.89 ± 0.22
All values normalized to actin expression and expressed relative to untreated cells as mean ± standard deviation. P values are listed underneath the corresponding
protein expression value for comparison with untreated cells if P <0.05. CDK, cyclin-dependent kinase; CK2, casein kinase 2; siRNA, small interfering RNA.
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treated three times by tail vein injection with 0.01 mg/kg
of TBG-siCDK11, TBG-siCK2, or TBG-siCON1 (a con-
trol nontargeting siRNA [57]). This dose and schedule
was chosen based on studies performed in prostate can-
cer models (unpublished data). Tumors were collected
10 days after initiation of treatment, and showed signifi-
cant reduction of tumor volume below the starting vol-
ume for TBG-siCDK11 (P = 0.001) and just above the
starting volume for TBG-siCK2 (P = 0.026, Figure 6A).
Tumor weights were also reduced in TBG-siCDK11-
treated (P = 0.030) and TBG-siCK2-treated mice com-
pared with TBG-siCON1-treated mice (Figure 6B). No
significant changes in mouse weights were observed fol-
lowing treatment with any of the nanocapsules
(Figure 6C). Finally, tumor proliferation was evaluated
by Ki-67 IHC and both TBG-siCDK11-treated
(P = 0.004) and TBG-siCK2-treated tumors demon-
strated reduced proliferation rates (Figure 6D).Table 5 mRNA expression levels in small interfering RNA
transfected cells
MDA-MB-231 SUM-149
siCDK11 siCK2 siCDK11 siCK2
CDK11 0.59 1.36 0.59 0.98
CK2α 2.09 0.15 1.37 0.13
CK2α′ 1.48 0.19 1.18 0.16
mRNA expression at 24 hours normalized to HPRT-1 and expressed relative to
siControl; mean of duplicate wells. si, small interfering.Treatment with TBG-siCDK11 or TBG-siCK2 induces RNA-
induced silencing complex cleavage of the relevant mRNA
transcripts in TNBC orthotopic xenograft tumors
RNA from TBG-siCDK11-treated and TBG-siCK2-
treated tumors was analyzed using the modified 5′
RACE technique to detect potential cleavage products.
Because there was not enough MDA-MB-231 TBG-
siCDK11-treated tumor remaining for this analysis, we
used SUM-149 mammary pad tumors from another
study. The data indicated that RNA-induced silencing
complex (RISC) cleavage products were detected for
CDK11 and for CK2α mRNAs in tumors specifically fol-
lowing TBG-siCDK11 and TBG-siCK2 treatments,
respectively (Figure 7A). No CDK11 or CK2 cleavage
products were detected in TBG-siCON1-treated tumors.
RISC cleavage products for CK2α were also detected in
MDA-MB-231 xenograft tumors (data not shown). No
CK2α′ cleavage products were detected in either SUM-
149 or MDA-MB-231 TBG-siCK2-treated tumors.
TBG-siCDK11-treated and TBG-siCK2-treated tumors show
loss of target protein expression and induction of death
signaling
Tumor lysates were subjected to immunoblot analysis to
evaluate the effects of nanocapsule treatment on target
gene expression (Figure 7B). TBG-siCDK11 treatment
resulted in CDK11p110 protein expression reduced to
66% relative to TBG-siCON1 (P = 0.002), cyclin L1α in-
creased to 216% (P = 0.040), and cyclin L2α reduced to
87% (Figure 7C). Cyclin L2α migration was slightly faster
in the TBG-siCDK11-treated and TBG-siCK2-treated
Figure 4 Small interfering RNA-mediated downregulation of
CDK11 and CK2 in breast cancer cells decreases cell viability
and inhibits clonal survival. (A) Breast cancer cells were
transfected with 30 nM single small interfering RNA (siRNA) or 15
nM each of the two siRNAs combined as indicated. After 96 hours,
cell viability was determined relative to the untreated cells. Means ±
standard errors (SEs) are presented. *P <0.05. **P <0.01, ***P <0.001
relative to untreated. ^P = 0.055, #P <0.05, ##P <0.01, ###P <0.001
relative to siCtrl. (B) Triple-negative breast cancer (TNBC) cells were
transfected twice with 30 nM single siRNAs or 15 nM each of the
two siRNAs combined as indicated and as described in Materials and
methods. Seven days after the second transfection, cell colonies
were stained and counted. Means ± SE are presented. $P <0.0001
relative to siCtrl and untreated. (C) Representative crystal violet
stained colonies on 35 mm plates 7 days after the second siRNA
transfection as described in (B). Cell lines are indicated above the
plate images and siRNA transfections are indicated to the left of the
plate images. CDK, cyclin-dependent kinase; CK2, casein kinase 2; si,
small interfering.
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TBG-siCK2 treatment resulted in CK2α protein expres-
sion reduced to 69% (P = 0.010), CK2α′ reduced to 74%,
and CK2β increased to 121%. Unexpectedly, TBG-
siCDK11-treated tumors showed reduced expression of
CK2α (P = 0.008) and CK2α′, and TBG-siCK2-treated
tumors showed reduced expression of CDK11p110
(P = 0.039). TBG-siCK2 treatment also increased cyclin
L1α expression (Figure 7C). These data demonstrate
reduced expression of targeted proteins, and some pos-
sible cross-influence between the two protein kinase
complexes.
The tumor lysates were further examined for effects
on downstream death signals. Bcl-xL protein was slightly
reduced to 91% and 81% following TBG-siCDK11 and
TBG-siCK2 treatments, respectively, although neither
were statistically significant (Figure 7C); no changes in
caspase 3 protein expression were detected (data not
shown). A small decrease to 86% was observed for survi-
vin in TBG-siCDK11-treated tumors, whereas a signifi-
cant decrease in survivin expression to 25% (P = 0.001)
was seen in TBG-siCK2-treated tumors (Figure 7C).
Discussion
This work represents the first report specifically investi-
gating CDK11 and CK2 as targets for in vivo TNBC
therapy. The significance of CDK11 as the proposed
therapeutic target lies in the possibility of affecting both
mitotically cycling and noncycling or quiescent malig-
nant cells because the expression and functions of
CDK11 isoforms affect both proliferating and quiescent
cells. This dual consequence of targeting CDK11 adds
unique functionality not observed by targeting family
members such as CDK1, CDK2, CDK4, or CDK6. Thus,
CDK11 downregulation would potentially overcome a
known failure point in some existing cancer therapeutics,
Figure 5 Nanocapsule morphology and uptake efficiency in cultured cells and in xenograft tumors. (A) Transmission electron micrographs of TBG-
siCDK11, TBG-siCK2, and TBG-siCON1 nanocapsules used for in vivo studies. Scale bar: 100 nm. (B) MDA-MB-231 fluorescence-activated cell sorting (FACS)
analysis for dysprosium (Dy) in untreated cells (black outline) and in TBG-Dy treated cells (gray). The number of TBG-Dy treatments is indicated above the
graphs. (C) FACS analysis of xenograft tumor cells from untreated mouse (left panels) and from intravenous TBG-Dy-treated mouse (right panels). The identity
of the tumor type is indicated above each panel. The position of the gate set to define Dy-positive cells is shown as a black line with Dy-positive events to
the right of the line. CDK, cyclin-dependent kinase; CK2, casein kinase 2; si, small interfering; SSC, side scatter; TBG, tenfibgen.
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utility of targeting CDK11 is further supported by a recent
investigation using intratumoral delivery of naked siRNAs
in osteosarcoma xenograft tumors that demonstrated the
efficacy of reduced CDK11 expression in this model [15].The significance of CK2 as the proposed target is found in
the extensive functions this master regulator performs in
cells, and its critical involvement in the oncogenic pheno-
type [37,43]. Notably, increased expression of CK2α in the
mouse mammary gland under control of the MMTV-LTR
Table 6 Nanocapsule characteristics and information
Shell ligand Particle size (nm)a Zeta potential (meV)b Morphologyc Cargod Sequencee
Tenfibgen 27.7 ± 4.6 −7.4 ± 4.2 Uniform, single capsules siCDK11 5′-gagcgagcagcagcgugugdTdT-3′
27 kDa
Tenfibgen 20.7 ± 5.2 −1.7 ± 2.4 Uniform, single capsules siCK2 5′-auacaacccaaacuccacaudTdT-3′
27 kDa
Tenfibgen 16.2 ± 2.4 −7.8 ± 4.2 Uniform, single capsules siCON1 5′-uagcgacuaaacacaucaauudTdT-3′
27 kDa
CDK, cyclin-dependent kinase; CK2, casein kinase 2; si, small interfering; TEM, transmission electron microscopy. aMean ± standard deviation of the average elliptical
diameter determined from TEM micrographs measuring at least 20 nanocapsules. bAverage surface charge measured by dynamic light scattering from two different
preparations across a 20 V potential in 1 mM KCl at 2 μg/ml. Data shown as the mean± standard error of 15 independent measurements. cMorphology of all nanocapsules
determined by visual atomic force microscopy and TEM observation as uniform, single capsules. dTBG-siCDK11, siCK2, and siCON1 encapsulation efficiencies mean of 54.0%,
86.8%, and 69.2%, respectively, observed by Burton analysis relative to unencapsulated siRNA. eSense strand sequence.
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[49]. Further, a recent report highlighted the anti-survival
effects of targeting CK2 in breast cancer [68], and oral
treatment of mice carrying BT-474 breast cancer xeno-
grafts with the CK2 inhibitor CX-4945 inhibited xenograft
tumor growth [69]. Data presented here showed that
knockdown of either of these kinases using siRNA tech-
nology was effective at inducing cell death in cultured cells
as well as TNBC xenograft tumors. Although we focused
primarily on TNBC in this work, CK2 and CDK11 target-
ing strategies are likely to be effective across the breast
cancer subtypes; however, further investigation will be
needed to verify this supposition.
Basing the choice of therapeutic target genes on those
that demonstrate increased mRNA expression levels in
cancer compared with normal tissue results in omission
of some candidates. mRNA levels cannot consistently be
used as surrogates for the corresponding protein expres-
sion levels; in fact, less than 50% of genes demonstrate
correlation between RNA and protein expression levels
[70,71]. Moreover, there is the added complication that
loss of translational control of gene expression is aTable 7 Fluorescence-activated cell sorting analysis of
TBG-Dy uptake
Cell line or tumor Treatment Dy-positive (%)
MDA-MB-231 Untreated 1.9
MDA-MB-231 TBG-Dy 1× 14.4
MDA-MB-231 TBG-Dy 2× 21.5
SUM-149 Untreated 0.9
SUM-149 TBG-Dy 13.1
SUM-149 tumor 1 Untreated 1.2
SUM-149 tumor 2 i.v. TBG-Dy 36.0
SUM-149 tumor 3 i.v. TBG-Dy 37.1
SUM-149 tumor 4 i.v. TBG-Dy 28.5
MDA-MB-231 tumor 1 Untreated 1.7
MDA-MB-231 tumor 2 i.v. TBG-Dy 11.0
Dy, dysprosium; i.v., intravenous; TBG, tenfibgen.common event in solid tumors, including breast cancer
[72]. Loss of translational control might account for the
close correlation of CDK11 transcript and protein levels
in the malignant cultured cell lines as compared with
the nontransformed cells MCF-10A and MCF-12A. In
normal tissue the CDK11 RNA levels are in the low
range and the protein levels are in mid to high ranges,
whereas in the cancer cell lines the RNA levels are in
the mid range and more closely match the protein levels
that are mid to high [62]. The RNAseq data we evalu-
ated for CDK11 indicated an increase in basal breast
cancer mRNA expression compared with the luminal B
subtype and not compared with normal breast or other
breast cancer subtypes; however, our IHC analysis of
breast tissue showed an increase in CDK11 protein ex-
pression intensity in TNBC compared with normal
breast. Future investigation into the post-transcriptional
regulation of CDK11 in breast cancer may reveal further
insights into the regulatory mechanisms in these
malignancies.
In the past, although CK2 protein expression has been
upregulated in all cancer types investigated to date
[43,73], CK2 was not typically identified as a good target
gene because microarray analysis did not show a signifi-
cant increase in its RNA expression. More recently, the
availability of RNAseq data has provided a new store of
unbiased data on transcript expression. Protein atlas
data show that, in normal tissue, CK2α RNA expression
is low and the protein expression levels are mid to high
[74]. CK2α expression in cancer cell lines shows mid-
level RNA expression and mid to high levels for protein,
demonstrating increased concordance of RNA and pro-
tein expression in cancer. Our RNAseq analyses here
demonstrated increased CK2α and CK2β mRNA expres-
sion in TNBC compared with normal tissue, validating
the utility of CK2 as a target in TNBC. While increased
CK2α protein expression in overall breast cancer is
established, the more specific roles of CK2α and CK2β
expression at the protein level in TNBC are not yet de-
fined [44,75].
Figure 6 Therapeutic effects of TBG-siCDK11 and TBG-siCK2 treatment in MDA-MB-231 xenograft tumors. (A) Primary tumor volumes are
shown following intravenous treatments at 0.01 mg/kg TBG-siCDK11, TBG-siCK2, or TBG-siCON1 on days 1, 4 and 7 (indicated by arrows). Means
± standard errors (SEs) are presented (TBG-siCDK11 and TBG-siCK2, n = 6; TBG-siCON1, n =7). *P <0.05, **P <0.01. (B) Primary tumor masses are
shown following treatments as described in (A). Thick line, mean; thin bar, SE (TBG-siCDK11 and TBG-siCK2, n = 6; TBG-siCON1, n = 7). #P <0.05. (C)
Masses of the mice throughout the study for each treatment group. Means are presented and error bars represent the SE. (D) Percentage of
Ki-67-positive cells was analyzed as described in Materials and methods and is shown graphically. Least-squares means are presented and error
bars represent SE. **P <0.01. CDK, cyclin-dependent kinase; CK2, casein kinase 2; si, small interfering; TBG, tenfibgen.
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cells did not notably increase the induction of cell death
over that observed targeting the kinases individually, so
the combination was not tested in vivo. Additionally, no
reduction in CK2αα′ mRNA at 24 hours or protein ex-
pression at 72 hours was observed when CDK11 was
downregulated using siRNA in cultured cells, and the re-
verse for CDK11 expression levels in siCK2 transfected
cells was also true. Interestingly, the treated tumor data
here suggest some reciprocal influence between mem-
bers of the CDK11 and CK2 protein complexes that was
not seen in cultured cells. We observed loss of
CDK11p110 upon downregulation of CK2αα′, and loss of
CK2αα′ upon downregulation of CDK11p110. Cyclin L1
protein expression was increased following downregula-
tion of either kinase. We have demonstrated previously
that CDK11 and CK2 protein kinase complexes interact
with one another within larger complexes regulating
RNA transcription and splicing [9,23,24]. Further, we
have shown that CK2 phosphorylates CDK11p110 [24].
Thus, it is possible that downregulation of one of these
survival kinases in vivo is acting to impact the expres-
sion of the other kinase, contributing to the decreased
survival of the TNBC cells. CK2 regulates survivin gene
expression in cultured cells such that loss of CK2 activity
decreases survivin expression [76,77]. The significantdownregulation of survivin protein following TBG-siCK2
treatment, but not following TBG-siCDK11 treatment,
suggests that downregulation of CK2 in the TBG-
siCDK11-treated tumors possibly occurred too late in the
acute response study to have markedly affected survivin
expression at the time of tumor collection.
Detection of CDK11 mRNA cleavage products in
TBG-siCDK11-treated tumors demonstrates that the
siRNA is acting through the RISC/Argonaute 2 pathway.
The siCDK11 siRNA sequence used in this experiment
has 3/19 mismatches comparing the human CDK11A
and CDK11B genes with the homologous mouse
CDK11B (Cdc2L1) sequence; human siCDK11 is thus
not likely to knockdown mouse CDK11 expression by
Argonaute 2/RISC-based mechanisms, and the RACE
products detected most probably derive from the human
xenograft tumor cells. For TBG-siCK2-treated tumors,
we were able to amplify CK2α but not CK2α′ mRNA
cleavage products. The siCK2 siRNA sequence has 1/20
mismatches with human CK2α′, and this may explain
why it is more difficult to detect CK2α′ cleavage prod-
uct. We did not have enough tumor material after pro-
tein analyses to perform human-specific quantitative
real-time PCR for the MDA-MB-231 treatment study;
however, the specific detection of the mRNA cleavage
products in both SUM-149 and MDA-MB-231 tumors
Figure 7 Analysis for RNA-induced silencing complex cleavage
products in treated tumors and immunoblot analysis for target
protein complexes and death signals in primary tumors. (A)
Total RNA was isolated from tumor tissue and used for 5′ ligation-
mediated RACE to determine whether RNA-induced silencing
complex (RISC)-mediated cleavage of the transcript occurred. The
predicted RACE products are indicated to the right, the size (base
pairs (bp)) of the DNA standards shown on the left, and the
treatment administered indicated above the lanes. (B) Immunoblot
analysis of MDA-MB-231 day 10 tumor lysates following intravenous
treatments of 0.01 mg/kg TBG-siCDK11, TBG-siCK2, or TBG-siCON1 as
indicated above the blots. The signals for three mice per group are
shown and the proteins detected are indicated on the right side of
the blots. Actin signal was used as the loading control. (C) The
protein signals from all mice in each treatment group were
quantitated by densitometry using ImageJ software (National
Institutes of Health Bethesda, MD, USA). Data presented as mean ±
standard error. *P <0.05, **P <0.01. CDK, cyclin-dependent kinase;
CK2, casein kinase 2; si, small interfering; TBG, tenfibgen.
Kren et al. Breast Cancer Research  (2015) 17:19 Page 18 of 21from mice treated intravenously using the TBG-
siCDK11 and TBG-siCK2 nanocapsules, respectively,
suggests that the appropriate transcripts are targeted for
reduction. The effect of TBG-siCDK11 and TBG-siCK2
treatment on target mRNA levels will be determined in
a future study.
There is ongoing research to develop small molecule in-
hibitors for several CDKs; however, to our knowledge no
specific inhibitor of CDK11 has emerged. Many inhibitors
to CK2 have been developed, and the inhibitor CX-4945 –
initially used in clinical trials as a single agent – is
currently in clinical trials as a combinatorial agent with
gemcitabine and cisplatin for treatment of cholangiocarci-
noma. It is well documented that cancer cells frequently
circumvent the effectiveness of small molecule inhibitors
over time, thus necessitating the development of alternate
strategies for cancer therapy [78,79]. Additionally, unlike
small molecule inhibitors, targeting the expression of an
individual protein using siRNAs provides a means to
precisely impact its expression and activity, providing
potential insight into novel interactions and/or pathways
that are specific for that protein.
Our TBG nanocapsule containing siRNAs directed
against either both CDK11 genes or against CK2α and
CK2α′ provides protection to the nucleic acid during circu-
lation and releases the siRNA within the cancer cells to
downregulate the targeted gene expression. Malignant
cell-directed treatment using the TBG nanoencapsulation
technology enables targeting of survival genes without asso-
ciated harm from downregulation of essential genes in
normal cells [1,3]. Interestingly, reduction of less than 35%
of either kinase in MDA-MB-231 tumors resulted in signifi-
cant effects on tumor volume relative to controls after only
three doses of the therapeutic agents. Further, treatment
with TBG-siCDK11 also significantly decreased proliferative
activity. These results demonstrate that moderate knock-
down of either CDK11 or CK2 significantly impacts the
growth and viability of TNBC tumors. Future work will
focus on investigating the use of TBG-siCDK11 and TBG-
siCK2 in various models of breast cancer as well as the
interplay between CDK11 and CK2 and their potential
co-regulation.
Conclusions
CDK11 expression and CK2 expression are individually
essential for breast cancer cell survival, including TNBC in
culture and in a MDA-MD-231 xenograft model. Our data
demonstrate that TBG nanoencapsulation of anti-CDK11
or anti-CK2 siRNAs is a highly specific means of success-
fully delivering the drug to malignant cells in vivo, and
moderate knockdown of either kinase resulted in significant
therapeutic benefit. We propose that CDK11 and CK2
serve as promising targets for further development of treat-
ment in breast cancer.
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